# Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

> **NCT05856084** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 924 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Low dose Recombinant Herpes Zoster Vaccine (CHO cells)
- **BIOLOGICAL:** High dose Recombinant Herpes Zoster Vaccine (CHO cells)
- **BIOLOGICAL:** Positive control
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05856084
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-07
- **Primary completion:** 2024-12-28
- **Final completion:** 2026-03-31
- **Target enrollment:** 924 (ESTIMATED)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856084, "Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05856084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*